Gemtuzumab ozogamicin

奥加吉妥珠单抗

Report date: 2026/04/24 20:01:59
First In Class

Base Information

Drug NameGemtuzumab ozogamicin
Drug Alias Name吉妥单抗gemtuzumab ozogamicinegemtuzumab ozogamicina单抗奥佐米星奥星-吉妥珠单抗 +[14] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > AcBut linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Calicheamicin payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA inhibitorsMyeloid cell surface antigen CD33 inhibitors
TargetsMyeloid cell surface antigen CD33DNA
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, JuvenileLeukemia, Myeloid, Acute +[5] 
Global Approved IndicationsLeukemia, Myeloid, Acute
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2005/07/25
Country/TerritoryCanadaUnited StatesSweden +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer IncUcb Sa
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncPfizer Europe Ma EeigWyeth-Ayerst Pharmaceuticals Inc
Inactive CompaniesWyeth LlcWeill Medical College of Cornell UniversityWake Forest University Health Sciences +[12] 
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, JuvenileLeukemia, Lymphocytic, Chronic, B-Cell +[4] 

Other Information

ATC CodeL01XC05
Related LinksWikipediaDrugBankKEGG